Trial Profile

Frontline Asciminib Combination in Chronic Phase CML

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Pharmacodynamics; Pharmacogenomic
Acronyms CMLXI; FASCINATION

Most Recent Events

12 Sep 2023 Planned number of patients changed from 150 to 155.
12 Sep 2023 Planned number of patients changed from 150 to 155.
15 Jun 2023 Interim results (n=144) of pre-planned analysis of primary endpoint according to the protocol presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com